Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVN-3085
- Development stage
- Preclinical
- Lead developer
- Avineuro Pharmaceuticals
- Modality
- Small Molecules
01
Overview
AVN-3085 is a small molecule drug candidate being developed by Avineuro Pharmaceuticals, in collaboration with ChemDiv, for the potential treatment of neurological disorders. It is classified as a G protein-coupled receptor (GPCR) modulator. The compound is part of a preclinical research program focused on discovering novel therapeutics for unmet needs in neurology and psychiatry. While several other candidates in the Avineuro pipeline specifically target serotonin receptors (such as 5-HT6 or 5-HT7), the specific GPCR subtype targeted by AVN-3085 has not been publicly disclosed. As of recent reports, the drug remains in the preclinical stage of development.
Beyond the preview
Go deeper on AVN-3085.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVN-3085.